Affordable Access

deepdyve-link
Publisher Website

[Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].

Authors
  • Veres, Gábor
  • Putz, Réka
  • Szabó, Dolóresz
  • Molnár, Kriszta
  • Bodánszky, Hedvig
  • Dezsofi, Antal
  • Arató, András
Type
Published Article
Journal
Orvosi hetilap
Publication Date
Oct 04, 2009
Volume
150
Issue
40
Pages
1858–1860
Identifiers
DOI: 10.1556/OH.2009.28731
PMID: 19789146
Source
Medline
License
Unknown

Abstract

Treatment with the chimeric monoclonal antibody (infliximab) is highly effective in refractory and fistulising Crohn's disease, nevertheless, infliximab resistance may occur. Authors report a 12-year-old boy with infliximab refractory luminal Crohn's disease including 3 active perianal fistulas. The patient was treated successfully with adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody. After 10 weeks of therapy, the previously high activity index returned to normal and the fistulas were closed. Quality of life using validated questionnaire improved significantly also. Adalimumab might be a suitable therapy even in pediatric Crohn's disease patients with infliximab resistance.

Report this publication

Statistics

Seen <100 times